Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer's Disease
Background: Mood disorders represent a risk factor for dementia and are present in over 60% of cases with Alzheimer's disease (AD). More than 80% variability in drug pharmacokinetics and pharmacodynamics is associated with pharmacogenetics. Methods: Anxiety and depression symptoms were assessed...
Saved in:
Main Authors: | Ramón Cacabelos (Author), Juan C. Carril (Author), Lola Corzo (Author), Lucía Fernández-Novoa (Author), Rocío Pego (Author), Natalia Cacabelos (Author), Pablo Cacabelos (Author), Margarita Alcaraz (Author), Iván Tellado (Author), Vinogran Naidoo (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neuroprotective Effect of Nosustrophine in a 3xTg Mouse Model of Alzheimer's Disease
by: Iván Carrera, et al.
Published: (2023) -
Nosustrophine: An Epinutraceutical Bioproduct with Effects on DNA Methylation, Histone Acetylation and Sirtuin Expression in Alzheimer's Disease
by: Olaia Martínez-Iglesias, et al.
Published: (2022) -
Natural Bioactive Products as Epigenetic Modulators for Treating Neurodegenerative Disorders
by: Olaia Martínez-Iglesias, et al.
Published: (2023) -
Potential effects of cannabinoids on audiovestibular function: A narrative review
by: Joaquin Guerra, et al.
Published: (2022) -
Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
by: Antón Álvarez, et al.
Published: (2010)